These pathways are ‘Estrogen Receptor’ targeted by tamoxifen and raloxifene; ‘Human Embryonic Stem Cell Pluripotency’ targeted by tamoxifen; ‘RAR Activation Pathway’ targeted by raloxifene and tamoxifen; ‘Bladder Cancer Signaling’ targeted by fulvestrant; ‘Factors Promoting Cardiogenesis in Vertebrates’ targeted by tamoxifen. The gene discussed is RARA; the disease is urinary bladder cancer.